A Retrospective Analysis of 2-Year Follow-Up of Patients with Incidental Findings of Sarcoidosis

• Published in: Diagnostics (Basel) Vol. 14; no. 3; p. 237
• Main Authors: Thomas-Orogan, Oluwabukola, Barratt, Shaney L, Zafran, Muhammad, Kwok, Apollo, Simons, Anneliese, Judge, Eoin P, Wells, Matthew, Daly, Richard, Sharp, Charles, Jeyabalan, Abiramy, Plummeridge, Martin, Chandratreya, Ladli, Spencer, Lisa G, Medford, Andrew R L, Adamali, Huzaifa I
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.01.2024
• Subjects: Algorithms; Asthma; Asymptomatic; Cost analysis; Development and progression; follow-up; Lung diseases; Medical research; Medicine, Experimental; Morbidity; Patients; Payment systems; Pepper spray; Pulmonary function tests; pulmonary sarcoidosis; Sarcoidosis; Serology; Sleep apnea; Tariffs; thoracic lymphadenopathy; Tomography; Tuberculosis; Type 2 diabetes; X-rays; United Kingdom; United Kingdom > UK; follow-up; sarcoidosis; thoracic lymphadenopathy; pulmonary sarcoidosis
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics14030237

Sarcoidosis is a multi-system granulomatous disease most commonly involving the lungs. It may be incidentally diagnosed during imaging studies for other conditions or non-specific symptoms. The appropriate follow-up of incidentally diagnosed asymptomatic stage 1 disease has not been well defined. To define the clinical course of incidentally diagnosed asymptomatic stage 1 sarcoidosis and propose an algorithm for the follow-up of these patients. A retrospective case note analysis was performed of all EBUS-TBNA (endobronchial ultrasound-guided transbronchial needle aspiration)-confirmed cases of stage 1 sarcoidosis presenting incidentally to Bristol and Liverpool Interstitial Lung Disease services. Clinical history, serology results, imaging scans, and lung function parameters were examined at baseline, 12, and 24 months. A cost analysis was performed comparing the cost of the current 2-year follow-up guidance to a 1 year follow-up period. Sixty-seven patients were identified as the final cohort. There was no significant change in the pulmonary function tests over the two-year follow-up period. Radiological disease stability was observed in the majority of patients (58%, = 29), and disease regression was evidenced in 40% ( = 20) at 1 year. Where imaging was performed at 2 years, the majority (69.8%, = 37) had radiological evidence of disease regression, and 30.2% ( = 16) showed radiological evidence of stability. All patients remained asymptomatic and did not require therapeutic intervention over the study period. Our results show that asymptomatic patients with incidental findings of thoracic lymph nodal non-caseating granulomas do not progress over a 2-year period. Our results suggest that the prolonged secondary-care follow-up of such patients may not be necessary. We propose that these patients are followed up for 1 year with a further year of patient-initiated follow-up (PIFU) prior to discharge.